Model-Based Evaluation of Antimicrobial Agents in Children
Model-Based Evaluation of Antimicrobial Agents in Children

Author: Wei Zhao

Publisher: Frontiers Media SA

Published: 2021-10-01

Total Pages: 160

ISBN-13: 2889714500

DOWNLOAD EBOOK

Topic Editor Johannes N. van den Anker is the Chief Medical Officer at Reveragen Biopharma, as well as holding his positions at academic institutions. The other Topic Editor declares no competing interests with regard to the Research Topic subject.

Antibiotic Pharmacodynamics
Antibiotic Pharmacodynamics

Author: John C. Rotschafer

Publisher: Humana

Published: 2016-03-30

Total Pages: 0

ISBN-13: 9781493933211

DOWNLOAD EBOOK

This text offers state of the art contributions written by world renown experts which provide an extensive background on specific classes of antibiotics and summarize our understanding as to how these antibiotics might be optimally used in a clinical situation. The book explores pharmacodynamics methods for anti-infective agents, pharmacodynamics of antibacterial agents and non-antibacterial agents, as well as pharmacodynamic considerations and special populations. As part of the Methods in Pharmacology and Toxicology series, chapters include detailed insight and practical information for the lab. Comprehensive and cutting-edge, Antibiotic Pharmacodynamics serves as an ideal reference for scientists investigating advances in antibiotic pharmacodynamics now finding their way into the antibiotic development process used for licensing new antibiotics.

Paediatric Formulation
Paediatric Formulation

Author: Nunzio Denora

Publisher: MDPI

Published: 2021-09-02

Total Pages: 205

ISBN-13: 303650740X

DOWNLOAD EBOOK

The development of paediatric medicines can be challenging since this is a different patient population with specific needs. A medicine designed for use in paediatric patients must consider the following aspects: patient population variability; the need for dose flexibility; route of administration; patient compliance; excipient tolerability. For example, the toxicity of excipients may differ in children compared to adults and children have different taste preferences. Globally, about 75% of drugs do not carry regulatory approval for use in children; worldwide, many medications prescribed for the treatment of paediatric diseases are used off-label, and less than 20% of package inserts have sufficient information for treating children. This book provides an update on both state-of-the-art methodology and operational challenges in paediatric formulation design and development. It aims at re-evaluating what is needed for more progress in the design and development of age-appropriate treatments for paediatric diseases, focusing on: formulation development; drug delivery design; efficacy, safety, and tolerability of drugs and excipients.

Paediatric Clinical Pharmacology
Paediatric Clinical Pharmacology

Author: Evelyne Jacqz-Aigrain

Publisher: CRC Press

Published: 2021-02-25

Total Pages: 830

ISBN-13: 0849374448

DOWNLOAD EBOOK

The treatment of children with medicinal products is an important scientific area. It is recognized that many medicines that are used extensively in pediatric patients are either unlicensed or off-label. This textbook will help pediatric health professionals effectively treat children with the most appropriate medicine with minimal side effects.

Manual of Childhood Infections
Manual of Childhood Infections

Author: Mike Sharland

Publisher: Oxford University Press, USA

Published: 2011-04-07

Total Pages: 913

ISBN-13: 0199573581

DOWNLOAD EBOOK

This manual gives information on the causative organisms, epidemiology and clinical features of all important childhood infections. It includes guidance on the clinical management of the infections and on steps to be taken to prevent future cases.

Paediatric drug optimization for neglected tropical diseases
Paediatric drug optimization for neglected tropical diseases

Author: World Health Organization

Publisher: World Health Organization

Published: 2023-11-21

Total Pages: 56

ISBN-13: 9240085173

DOWNLOAD EBOOK

Priority-setting is the first step to enable a targeted approach to research and development. Developing a prioritized drug portfolio of the most needed formulations for children is essential to streamline researchers’ and supplier’s efforts and resources around specific dosage forms and formulations that address most urgent needs for children. In general, due to limited financial incentives, few new drugs are being developed for Neglected Tropical Diseases (NTDs). Several NTDs disproportionately affect children compared to adults and, as is the case like for most diseases affecting adults and children, the burden to children is compounded by lack of inclusion of paediatric populations in clinical trials and/or lack of age-appropriate dosing regimens and formulations. The PADO-NTD exercise concluded with a final meeting organized in September 2023 with representatives from the four prioritized disease areas to reach consensus on a final PADO-NTD priority list, watch list and research questions and discuss transversal issues for the way forward. The meeting report will include summaries of the background, discussions and deliberations of all PADO exercises, and final conclusions and outputs of the overall PADO for NTD exercises.

Paediatric drug optimization for cancer medicines
Paediatric drug optimization for cancer medicines

Author: World Health Organization

Publisher: World Health Organization

Published: 2024-10-16

Total Pages: 33

ISBN-13: 9240101055

DOWNLOAD EBOOK

The goal of the Paediatric drug optimization for cancer exercise was to develop a PADO priority list of formulations to be prioritized with a time horizon of 3–5 years, and a PADO ‘watch list’ containing promising candidates for investigation and development for children with a time horizon of 5–10 years. The PADO–cancer exercise enables alignment between funders, procurers, market-coordination entities, researchers, innovators, generics manufacturers, product development partnerships and regulators on priority products to be investigated and developed, as well as increasing efforts to tackle challenges in access to cancer medicines in LMICs.